Approved

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Novartis' Xolair Scores European Approval to Treat Chronic Rhinosinusitis with Nasal Polyps

Lead Product(s): Omalizumab

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xolair

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 06, 2020

Details:

EC approves Xolair® (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first anti-immunoglobulin E antibody approved in this indication.

KALEO INC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Optinose Announces XHANCE Co-Promotion Agreement with Kaléo

Lead Product(s): Fluticasone Propionate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Optinose

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 08, 2020

Details:

Under the terms of the agreement, kaléo will promote XHANCE to an agreed-upon audience of office-based healthcare professionals, rapidly increasing promotional reach and frequency.

ALK

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO®, the First and Only Single-Dose Treatment for Acute Otitis Externa

Lead Product(s): Ciprofloxacin

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Otiprio

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Otonomy

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 17, 2020

Details:

Under the terms of the agreement, ALK will have exclusive rights to promote OTIPRIO for AOE to office-based healthcare professionals in the U.S. including ENT physicians, pediatricians and select primary care physicians.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Novartis Pharmaceuticals Corporation

Novartis' Xolair Scores European Approval to Treat Chronic Rhinosinusitis with Nasal Polyps

KALEO INC

Optinose Announces XHANCE Co-Promotion Agreement with Kaléo

ALK

ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO®, the First and Only Single-Dose Treatment for Acute Otitis Externa